Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single versus divided-dose amikacin for renal complications in neonatal sepsis
IRCT20201212049686N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amikacin in neonatal sepsis (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Renal complications, Glomerular filtration rate and 3 more. Started Jul 2019; status: completed.
02
Drugs
amikacin
03
Conditions
neonatal sepsis
Beyond the preview
Go deeper on IRCT20201212049686N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201212049686N1.